Alaunos Therapeutics (TCRT) Preferred Stock Liabilities (2016 - 2018)

Alaunos Therapeutics (TCRT) has 3 years of Preferred Stock Liabilities data on file, last reported at $160.4 million in Q3 2018.

• Quarterly Preferred Stock Liabilities rose 15.36% year-over-year to $160.4 million in Q3 2018, while the trailing twelve-month figure through Sep 2018 was $160.4 million (up 15.36% YoY) and the FY2017 annual result came in at $144.0 million, up 14.9% from the prior year.
• Preferred Stock Liabilities grew to $160.4 million in Q3 2018, from $154.4 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $160.4 million in Q3 2018 to a low of $121.8 million in Q3 2016.
• A 3-year average of $139.8 million and a median of $139.1 million in 2017 frame the typical range for Preferred Stock Liabilities.
• Annual changes were most pronounced in 2017 — Preferred Stock Liabilities climbed 14.16% — and 2018, when it grew 15.36%.
• Tracing TCRT's Preferred Stock Liabilities over 3 years: stood at $125.3 million in 2016, then climbed by 14.9% to $144.0 million in 2017, then gained by 11.42% to $160.4 million in 2018.
• The last three Preferred Stock Liabilities figures came in at $160.4 million (Q3 2018), $154.4 million (Q2 2018), and $149.0 million (Q1 2018), per Business Quant data.